We are live on ! Find out more
Commodore Capital

Commodore Capital Portfolio holdings

AUM $1.29B Turnover 37.21%
1-Year Est. Return 224.34%
 

Commodore Capital runs funds that back drug developers, from early-stage public companies to late-stage private ones. It aims to fill a gap it sees between traditional venture capital and public market funds. Its thesis is that small biopharma companies, not large drugmakers, drive much of the innovation in areas like genetic medicines and cell therapies. Michael Kramarz and Egen Atkinson, both medical doctors with MBAs, are its managing partners. They indirectly own a majority of the firm, which began operating in 2019. The funds are open to institutions, pension plans, endowments and high net worth individuals.

This Fund
S&P 500
This Quarter Est. Return
+40.89%
1 Year Est. Return
+224.34%
3 Year Est. Return
+1,776.41%
5 Year Est. Return
+7,447.99%
10 Year Est. Return
–
AUM
$1.68B
AUM Growth
-$49.5M
Cap. Flow
-$478M
Cap. Flow %
-28.49%
Top 10 Hldgs %
68.18%
Holding
41
New
5
Increased
6
Reduced
9
Closed
8
Avg Time Held
1.1 years
Top 10 Avg Time Held
0.7 years
Top 20 Avg Time Held
0.8 years

Top Buys

Rank Stock Value
1
TNGX icon
Tango Therapeutics
TNGX
+$55.6M
2
EDIT icon
Editas Medicine
EDIT
+$26M
3
EYPT icon
EyePoint
EYPT
+$23.7M
4
IFRX icon
InflaRx
IFRX
+$13.7M
5
ASMB icon
Assembly Biosciences
ASMB
+$11.3M

Top Sells

Rank Stock Value
1
NUVL icon
Nuvalent
NUVL
+$78.9M
2
SYRE icon
Spyre Therapeutics
SYRE
+$77.8M
3
RLAY icon
Relay Therapeutics
RLAY
+$72.6M
4
ERAS icon
Erasca
ERAS
+$51.4M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$48M

Sector Composition

Rank Sector Weight
1 Healthcare 99.36%
2 Financials 0.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
RLAY icon
1
Relay Therapeutics
RLAY
$3.82B
$225M 13.37%
12,000,000
-5,000,000
-29% -$72.6M
2025 Q2
4 quarters
ELVN icon
2
Enliven Therapeutics
ELVN
$3.5B
$166M 9.9%
3,275,000
– –
2022 Q4
14 quarters
ALKS icon
3
Alkermes
ALKS
$7.82B
$157M 9.36%
3,000,000
-1,200,000
-29% -$46.9M
2024 Q2
8 quarters
COGT icon
4
Cogent Biosciences
COGT
$4.77B
$118M 7.03%
3,050,000
+161,993
+6% +$5.67M
2020 Q4
22 quarters
AMLX icon
5
Amylyx Pharmaceuticals
AMLX
$3.57B
$101M 6.04%
5,650,000
– –
2025 Q3
3 quarters
DFTX icon
6
Definium Therapeutics
DFTX
$4.13B
$94.1M 5.6%
2,000,000
– –
2024 Q1
9 quarters
SYRE icon
7
Spyre Therapeutics
SYRE
$9.44B
$75.2M 4.48%
846,786
-1,065,594
-56% -$77.8M
2023 Q2
12 quarters
ANRO icon
8
Alto Neuroscience
ANRO
$1.09B
$71.9M 4.28%
2,723,196
– –
2025 Q4
2 quarters
TNGX icon
9
Tango Therapeutics
TNGX
$4.1B
$70.3M 4.19%
+2,250,000
New +$55.6M
2026 Q2
0 quarters
EYPT icon
10
EyePoint
EYPT
$35M
$65.8M 3.92%
4,600,000
+1,775,000
+63% +$23.7M
2026 Q1
1 quarter
TYRA icon
11
Tyra Biosciences
TYRA
$1.36B
$59.9M 3.57%
1,875,000
-600,000
-24% -$19.8M
2025 Q1
5 quarters
DMRA icon
12
Damora Therapeutics
DMRA
$1.39B
$50.4M 3%
1,939,000
– –
2026 Q1
1 quarter
CLDX icon
13
Celldex Therapeutics
CLDX
$2.25B
$50.2M 2.99%
1,350,000
-1,346,616
-50% -$43.5M
2025 Q1
5 quarters
PHVS icon
14
Pharvaris
PHVS
$2.3B
$49.3M 2.93%
1,425,000
-493,970
-26% -$14.9M
2023 Q4
10 quarters
LBRX icon
15
LB Pharmaceuticals
LBRX
$1.39B
$48.7M 2.9%
1,500,000
– –
2025 Q3
3 quarters
ASMB icon
16
Assembly Biosciences
ASMB
$436M
$38.9M 2.32%
1,415,000
+415,000
+42% +$11.3M
2025 Q3
3 quarters
EDIT icon
17
Editas Medicine
EDIT
$289M
$28.8M 1.72%
+8,889,000
New +$26M
2026 Q2
0 quarters
KYMR icon
18
Kymera Therapeutics
KYMR
$10.7B
$28.7M 1.71%
250,000
-500,000
-67% -$43M
2025 Q2
4 quarters
CATX icon
19
Perspective Therapeutics
CATX
$112M
$21.6M 1.29%
6,336,782
– –
2026 Q1
1 quarter
IPSC icon
20
Century Therapeutics
IPSC
$298M
$21.3M 1.27%
8,695,652
– –
2026 Q1
1 quarter
ZURA icon
21
Zura Bio
ZURA
$104M
$19.2M 1.14%
3,250,000
– –
2026 Q1
1 quarter
AVTX icon
22
Avalo Therapeutics
AVTX
$426M
$18.8M 1.12%
1,018,319
+535,319
+111% +$8.46M
2024 Q2
8 quarters
IFRX icon
23
InflaRx
IFRX
$174M
$16.4M 0.97%
+7,300,000
New +$13.7M
2026 Q2
0 quarters
ANTX icon
24
AN2 Therapeutics
ANTX
$170M
$14.2M 0.85%
2,933,680
+599,967
+26% +$2.58M
2026 Q1
1 quarter
NUVL icon
25
DELISTED
Nuvalent
NUVL
$12.4M 0.74%
100,000
-733,600
-88% -$78.9M
2022 Q4
14 quarters

Similar funds

Commodore Capital's Q2 2026 Portfolio in Review

As of Q2 2026, Commodore Capital held 41 positions worth $1.68B, down 2.9% from $1.73B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Commodore Capital withdrew a net $478M in Q2 2026, closing 8 positions and reducing 9 holdings. Its most notable exit was Erasca, an estimated $51.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Financials.

Against the trend, Commodore Capital opened a new position in Tango Therapeutics worth $70.3M.

  • Commodore Capital's largest Q2 2026 buy was Tango Therapeutics: 2,250,000 shares worth $70.3M.
  • Commodore Capital added most to EyePoint in Q2 2026, an estimated $23.7M increase.
  • Commodore Capital's biggest Q2 2026 reduction was Nuvalent, cutting an estimated $78.9M.
  • Commodore Capital fully exited Erasca in Q2 2026, selling an estimated $51.4M.
  • Commodore Capital's ten largest holdings make up 68% of its $1.68B portfolio in Q2 2026.
  • Commodore Capital opened 5 new positions and closed 8 in Q2 2026.
  • Commodore Capital's portfolio value fell 2.9% quarter-over-quarter to $1.68B.

Based on Commodore Capital's 13F filing for Q2 2026, filed 14 Aug 2026.